This document provides an overview of Zynex, Inc., a medical device company that manufactures non-invasive electrotherapy and monitoring devices. It summarizes Zynex's business units, products, financial performance, growth strategy, and management team. The document contains forward-looking statements about Zynex's estimates and assumptions that involve risks and uncertainties. It warns investors to not rely solely on these statements due to various risk factors that could cause actual results to differ materially.
Zynex Inc. was founded in 1996 on the principle that a commitment to high-quality patient life through non-invasive rehabilitation products can be a profitable as well as rewarding endeavor.
Today, Zynex is a leading provider of electrotherapy medical devices used for pain management and rehabilitation. The company’s proprietary NeuroMove device is used to help recovery of stroke and spinal cord injury patients. Zynex is also pioneering development of an innovative blood volume monitor for use in hospitals and surgery centers. Zynex is committed to improve the quality of life of patients in the markets it serves by providing the highest technology and service standards available in the industry.
December 2015 ZYXI Investor PresentationPritesh Patel
The document provides an overview of Zynex, Inc., a medical device manufacturer. It notes that statements and estimates in the presentation involve risks and uncertainties. It summarizes Zynex's business units, products, financial performance, growth objectives, and management team. The purpose is to provide investors with information about Zynex while cautioning that actual results may differ from estimates.
The document discusses forward-looking financial estimates and statements made by a company. It notes that such estimates involve risk and uncertainties as they are based on assumptions about future conditions that may change. Actual results may differ significantly from the company's estimates. Key risk factors are described in the company's SEC filings. The company has no obligation to update its estimates.
Agility Health July 2017 Corporate PresentationAgilityHealth
Agility Health provides physical rehabilitation services through a network of over 160 clinics across North America. The presentation provides an overview of Agility's business segments, financial performance, growth strategies, and management team. Key points include that Agility has over 1 million patient visits annually, generates over $100 million in annual revenue, and aims to expand its network of clinics through both organic growth and acquisitions. The management team is focused on improving profitability and pursuing a roll-up strategy in the fragmented physical therapy market.
Powerful Medical Branding for Your Medical Device Investor Deck. Example: Amnis Therapeutics Investor Deck by Berliner Design (www.berlinerdesign.co.il).
The document provides an investment analysis on Optimer Pharmaceuticals, Inc. Key points include:
- An FDA advisory panel voted 13-0 that fidaxomicin was safe and effective for treating C. difficile infection, indicating an 85% likelihood of its approval by the May 30 deadline.
- The panel was ambivalent about whether fidaxomicin reduced infection recurrence, which could impact its labeling but not the analyst's expectations for use in vancomycin failures.
- The analyst maintains a $16 price target and "Buy" rating on Optimer, expecting peak fidaxomicin sales of $250 million by 2016, while acknowledging risks include regulatory issues and commercial challenges.
The document provides information on various skin care products from a dermatologist-formulated line, including cleansers, toners, serums, moisturizers and exfoliants. It describes the key ingredients and benefits of each product, and recommends how to use them as part of a skincare routine.
The Importance of Sales Training Programs To Promote Salesflatt25
A sales Training Program can enhance the performance of an organization. Through sales training practices and personal coaching, there will be more confidence with potential clients.
Zynex Inc. was founded in 1996 on the principle that a commitment to high-quality patient life through non-invasive rehabilitation products can be a profitable as well as rewarding endeavor.
Today, Zynex is a leading provider of electrotherapy medical devices used for pain management and rehabilitation. The company’s proprietary NeuroMove device is used to help recovery of stroke and spinal cord injury patients. Zynex is also pioneering development of an innovative blood volume monitor for use in hospitals and surgery centers. Zynex is committed to improve the quality of life of patients in the markets it serves by providing the highest technology and service standards available in the industry.
December 2015 ZYXI Investor PresentationPritesh Patel
The document provides an overview of Zynex, Inc., a medical device manufacturer. It notes that statements and estimates in the presentation involve risks and uncertainties. It summarizes Zynex's business units, products, financial performance, growth objectives, and management team. The purpose is to provide investors with information about Zynex while cautioning that actual results may differ from estimates.
The document discusses forward-looking financial estimates and statements made by a company. It notes that such estimates involve risk and uncertainties as they are based on assumptions about future conditions that may change. Actual results may differ significantly from the company's estimates. Key risk factors are described in the company's SEC filings. The company has no obligation to update its estimates.
Agility Health July 2017 Corporate PresentationAgilityHealth
Agility Health provides physical rehabilitation services through a network of over 160 clinics across North America. The presentation provides an overview of Agility's business segments, financial performance, growth strategies, and management team. Key points include that Agility has over 1 million patient visits annually, generates over $100 million in annual revenue, and aims to expand its network of clinics through both organic growth and acquisitions. The management team is focused on improving profitability and pursuing a roll-up strategy in the fragmented physical therapy market.
Powerful Medical Branding for Your Medical Device Investor Deck. Example: Amnis Therapeutics Investor Deck by Berliner Design (www.berlinerdesign.co.il).
The document provides an investment analysis on Optimer Pharmaceuticals, Inc. Key points include:
- An FDA advisory panel voted 13-0 that fidaxomicin was safe and effective for treating C. difficile infection, indicating an 85% likelihood of its approval by the May 30 deadline.
- The panel was ambivalent about whether fidaxomicin reduced infection recurrence, which could impact its labeling but not the analyst's expectations for use in vancomycin failures.
- The analyst maintains a $16 price target and "Buy" rating on Optimer, expecting peak fidaxomicin sales of $250 million by 2016, while acknowledging risks include regulatory issues and commercial challenges.
The document provides information on various skin care products from a dermatologist-formulated line, including cleansers, toners, serums, moisturizers and exfoliants. It describes the key ingredients and benefits of each product, and recommends how to use them as part of a skincare routine.
The Importance of Sales Training Programs To Promote Salesflatt25
A sales Training Program can enhance the performance of an organization. Through sales training practices and personal coaching, there will be more confidence with potential clients.
The document provides an overview of Zynex, Inc., a medical device company that develops non-invasive devices for pain relief, rehabilitation, and monitoring. It discusses Zynex's product lines, financial performance, growth strategy, and $4 billion total addressable market opportunity. The document is intended to provide investors with information about Zynex's business and financials.
johnson & johnson Q4 2008 Investor Relations Business Overview finance4
This document contains a safe harbor statement for Johnson & Johnson noting that the press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It also provides a list of specific risks and uncertainties the company faces and directs readers to further information in the company's annual report. The statement does not guarantee the company's financial performance but aims to fairly advise investors and analysts of known risks.
Tenet Healthcare Corporation reported financial results for the 4th quarter of 2006 with a loss of $386 million compared to a loss of $286 million in the 4th quarter of 2005. Net operating revenues increased 2.6% to $2.179 billion. Adjusted EBITDA was $153 million, up 24.4% from $123 million in 2005. Admissions declined 0.9% to 143,110. While pricing increased, admissions declines and unfavorable mix shifts toward government programs continued to affect financial performance.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion for clinical cancer testing and an experienced management team.
- Financial results show strong revenue and test volume growth as well as expanding adjusted EBITDA margins.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion that is growing due to cancer prevalence increasing with an aging population and more cancer tests through precision medicine.
- Recent financial performance shows year-over-year revenue growth of 142% and adjusted EBITDA growth of 224% for the first three quarters of 2016, which includes the effects of the Clarient acquisition.
- Nobilis Health Corp owns and operates ambulatory surgical centers and surgical hospitals across 7 states.
- They utilize a unique direct-to-patient marketing model to drive organic growth and capitalize on the trend of increased healthcare consumerism.
- For 2015, Nobilis reported revenue of $229.2 million and adjusted EBITDA of $42.1 million. They expect continued growth through organic expansion and acquisitions in a fragmented market.
Centene Corporation (CNC) is a health insurance company that provides government-sponsored healthcare programs to under-insured individuals. It is acquiring HealthNet, which will expand its Medicaid membership to 11 million across 23 states. The acquisition is expected to close in June 2016 and provide significant revenue growth and cost synergies. Centene has a diversified business model across government programs and geographies. It has achieved strong revenue and earnings growth through acquisitions and expansion into new markets. The analyst recommends buying CNC with a target price of $79.8 based on the company's steady growth prospects and undervaluation.
Tenet Healthcare Corporation reported financial results for the fourth quarter and full year of 2008. For Q4 2008, revenue increased 27.6% to $199 million compared to Q4 2007. Same-hospital revenue grew 27.2% over the prior year. For the full year 2008, revenue grew 11.4% to $732 million over 2007. Volume metrics like admissions were flat to up slightly for Q4 2008 compared to prior year. Tenet provided an outlook for 2009 adjusted EBITDA in the range of $735-$800 million.
Tenet Healthcare Corporation reported financial results for the fourth quarter and full year of 2008. For the quarter, revenue increased 4.9% to $2.17 billion due to pricing increases, while expenses were well controlled. Adjusted EBITDA rose 27.6% to $199 million. For the full year, net income was $25 million compared to a prior year loss, and adjusted EBITDA increased 11.4% to $732 million. Tenet provided guidance for 2009 adjusted EBITDA in the range of $735-800 million.
Tenet Healthcare Corporation reported financial results for the fourth quarter of 2008 with some improvements but also challenges. Same-hospital adjusted EBITDA grew 27.2% year-over-year to $201 million. Paying admissions grew 0.1% while total admissions declined 0.2%. Surgeries grew 2.1% led by a 3.7% increase in outpatient surgeries. For 2009, Tenet expects adjusted EBITDA in the range of $735-800 million but anticipates pressure on bad debt and commercial volumes.
The document analyzes Sterling's potential acquisition of a unit from Montagne Medical Instruments Company that manufactures and markets germicidal, sanitation, and antiseptic products. It finds that acquiring the unit at the quoted price of $265M is not worthwhile based on a net present value analysis. However, the acquisition would be worthwhile if Sterling invests more money post-acquisition to expand the unit's operations. A sensitivity analysis supports proceeding with expansion given expectations of inflation, costs, and pricing. The conclusion is that Sterling should only acquire the unit if willing to further invest in expanding its capacity.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
- GE is planning to spin off its healthcare business to become a standalone company called GE HealthCare in early January 2023.
- GE HealthCare is a global leader in medical technologies and digital solutions with over $18B in annual revenue and operations in over 160 countries.
- As an independent company, GE HealthCare aims to accelerate revenue growth, expand margins to a high-teens to 20% range through business optimization, and generate strong free cash flow to create sustainable long-term shareholder value.
Valuetronics reported strong financial results for FY2014, with revenue increasing 10.1% and net profit rising 24.9%. The company has a large cash position of $478M and generated $303M in operating cash flow. The analyst upgrades their rating to "Buy" and sets a target price of $0.605, citing earnings outperformance, excess cash, and an attractive 8% dividend yield. The analyst expects continued revenue growth from the consumer electronics and industrial/commercial segments as those industries benefit from trends like LED lighting adoption and manufacturing outsourcing.
Nordion is a global health science company that provides medical isotopes and sterilization technologies. It has approximately 450 employees serving over 500 customers in more than 40 countries. Nordion is focused on optimizing its medical isotopes business and maintaining its sterilization business. It is also committed to environmental, health and safety standards. Nordion's talented employees work to maintain a global leadership position and build shareholder value.
- The document provides an equity report analyzing Synergetics Inc., a medical device company focused on ophthalmic and neurosurgery markets.
- It summarizes Synergetics' business segments, recent acquisitions, industry data on ophthalmic and neurosurgery markets, and financial analysis including revenue growth, profitability, and financial position.
- Key highlights include Synergetics growing its ophthalmic segment through acquisition, industry growth in disposable medical devices, and Synergetics expanding operating margins through cost reductions while revenue grew 15.8% in fiscal year 2015.
The document summarizes Belgium's public and private health care insurance system and AG Insurance's role within it. It notes that:
1) Belgium has a public health care system that covers up to 75% of medical costs, with the remainder paid through required private insurance or out-of-pocket.
2) AG Insurance is a leader in the Belgian private health insurance market, insuring over 1.2 million people as of 2011.
3) AG Insurance has experienced strong growth through cross-selling other insurance products and expanding into new market segments, and focuses on sustainable pricing, customer service, and product innovation to remain successful.
Tenet Healthcare Corporation reported net income of $70 million for the first quarter of 2006, compared to a net loss of $4 million in the first quarter of 2005. Revenues increased 0.2% to $2.357 billion for same-hospital operations due to a 3.1% increase in compact-adjusted net operating revenues, which excludes discounts provided to uninsured patients. Same-hospital admissions declined 3.3% to 161,756 due to factors such as competition and challenges retaining physicians.
Gruppo Banca IFIS - 2017 preliminary results presentationBanca Ifis
This document provides a summary of key financial information for a company for the fiscal year 2017. Preliminary results show net profit of €180.8 million, an increase of 5.5% compared to the previous fiscal year when normalized. Total assets grew 8.6% to €6.4 billion. The common equity tier 1 ratio remained strong at 15.64%. Business segments like trade receivables and corporate banking saw loan growth while maintaining stable credit quality.
- Q3 2017 company sales grew 4.7% at CER to €9.1 billion, driven by specialty care and vaccines franchises. Diabetes sales declined 14.8% due to losses of exclusivity.
- Specialty care grew 13.9% led by strong Dupixent sales in the US and Kevzara gaining 15% of the IL-6 market share. Vaccines grew 7.2% with strong pediatric combination vaccine sales.
- Consumer healthcare grew 1% with emerging markets up 6.7% offsetting declines in developed markets due to increased competition.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
More Related Content
Similar to Zynex December 2013 Investor Presentation
The document provides an overview of Zynex, Inc., a medical device company that develops non-invasive devices for pain relief, rehabilitation, and monitoring. It discusses Zynex's product lines, financial performance, growth strategy, and $4 billion total addressable market opportunity. The document is intended to provide investors with information about Zynex's business and financials.
johnson & johnson Q4 2008 Investor Relations Business Overview finance4
This document contains a safe harbor statement for Johnson & Johnson noting that the press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It also provides a list of specific risks and uncertainties the company faces and directs readers to further information in the company's annual report. The statement does not guarantee the company's financial performance but aims to fairly advise investors and analysts of known risks.
Tenet Healthcare Corporation reported financial results for the 4th quarter of 2006 with a loss of $386 million compared to a loss of $286 million in the 4th quarter of 2005. Net operating revenues increased 2.6% to $2.179 billion. Adjusted EBITDA was $153 million, up 24.4% from $123 million in 2005. Admissions declined 0.9% to 143,110. While pricing increased, admissions declines and unfavorable mix shifts toward government programs continued to affect financial performance.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion for clinical cancer testing and an experienced management team.
- Financial results show strong revenue and test volume growth as well as expanding adjusted EBITDA margins.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion that is growing due to cancer prevalence increasing with an aging population and more cancer tests through precision medicine.
- Recent financial performance shows year-over-year revenue growth of 142% and adjusted EBITDA growth of 224% for the first three quarters of 2016, which includes the effects of the Clarient acquisition.
- Nobilis Health Corp owns and operates ambulatory surgical centers and surgical hospitals across 7 states.
- They utilize a unique direct-to-patient marketing model to drive organic growth and capitalize on the trend of increased healthcare consumerism.
- For 2015, Nobilis reported revenue of $229.2 million and adjusted EBITDA of $42.1 million. They expect continued growth through organic expansion and acquisitions in a fragmented market.
Centene Corporation (CNC) is a health insurance company that provides government-sponsored healthcare programs to under-insured individuals. It is acquiring HealthNet, which will expand its Medicaid membership to 11 million across 23 states. The acquisition is expected to close in June 2016 and provide significant revenue growth and cost synergies. Centene has a diversified business model across government programs and geographies. It has achieved strong revenue and earnings growth through acquisitions and expansion into new markets. The analyst recommends buying CNC with a target price of $79.8 based on the company's steady growth prospects and undervaluation.
Tenet Healthcare Corporation reported financial results for the fourth quarter and full year of 2008. For Q4 2008, revenue increased 27.6% to $199 million compared to Q4 2007. Same-hospital revenue grew 27.2% over the prior year. For the full year 2008, revenue grew 11.4% to $732 million over 2007. Volume metrics like admissions were flat to up slightly for Q4 2008 compared to prior year. Tenet provided an outlook for 2009 adjusted EBITDA in the range of $735-$800 million.
Tenet Healthcare Corporation reported financial results for the fourth quarter and full year of 2008. For the quarter, revenue increased 4.9% to $2.17 billion due to pricing increases, while expenses were well controlled. Adjusted EBITDA rose 27.6% to $199 million. For the full year, net income was $25 million compared to a prior year loss, and adjusted EBITDA increased 11.4% to $732 million. Tenet provided guidance for 2009 adjusted EBITDA in the range of $735-800 million.
Tenet Healthcare Corporation reported financial results for the fourth quarter of 2008 with some improvements but also challenges. Same-hospital adjusted EBITDA grew 27.2% year-over-year to $201 million. Paying admissions grew 0.1% while total admissions declined 0.2%. Surgeries grew 2.1% led by a 3.7% increase in outpatient surgeries. For 2009, Tenet expects adjusted EBITDA in the range of $735-800 million but anticipates pressure on bad debt and commercial volumes.
The document analyzes Sterling's potential acquisition of a unit from Montagne Medical Instruments Company that manufactures and markets germicidal, sanitation, and antiseptic products. It finds that acquiring the unit at the quoted price of $265M is not worthwhile based on a net present value analysis. However, the acquisition would be worthwhile if Sterling invests more money post-acquisition to expand the unit's operations. A sensitivity analysis supports proceeding with expansion given expectations of inflation, costs, and pricing. The conclusion is that Sterling should only acquire the unit if willing to further invest in expanding its capacity.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
- GE is planning to spin off its healthcare business to become a standalone company called GE HealthCare in early January 2023.
- GE HealthCare is a global leader in medical technologies and digital solutions with over $18B in annual revenue and operations in over 160 countries.
- As an independent company, GE HealthCare aims to accelerate revenue growth, expand margins to a high-teens to 20% range through business optimization, and generate strong free cash flow to create sustainable long-term shareholder value.
Valuetronics reported strong financial results for FY2014, with revenue increasing 10.1% and net profit rising 24.9%. The company has a large cash position of $478M and generated $303M in operating cash flow. The analyst upgrades their rating to "Buy" and sets a target price of $0.605, citing earnings outperformance, excess cash, and an attractive 8% dividend yield. The analyst expects continued revenue growth from the consumer electronics and industrial/commercial segments as those industries benefit from trends like LED lighting adoption and manufacturing outsourcing.
Nordion is a global health science company that provides medical isotopes and sterilization technologies. It has approximately 450 employees serving over 500 customers in more than 40 countries. Nordion is focused on optimizing its medical isotopes business and maintaining its sterilization business. It is also committed to environmental, health and safety standards. Nordion's talented employees work to maintain a global leadership position and build shareholder value.
- The document provides an equity report analyzing Synergetics Inc., a medical device company focused on ophthalmic and neurosurgery markets.
- It summarizes Synergetics' business segments, recent acquisitions, industry data on ophthalmic and neurosurgery markets, and financial analysis including revenue growth, profitability, and financial position.
- Key highlights include Synergetics growing its ophthalmic segment through acquisition, industry growth in disposable medical devices, and Synergetics expanding operating margins through cost reductions while revenue grew 15.8% in fiscal year 2015.
The document summarizes Belgium's public and private health care insurance system and AG Insurance's role within it. It notes that:
1) Belgium has a public health care system that covers up to 75% of medical costs, with the remainder paid through required private insurance or out-of-pocket.
2) AG Insurance is a leader in the Belgian private health insurance market, insuring over 1.2 million people as of 2011.
3) AG Insurance has experienced strong growth through cross-selling other insurance products and expanding into new market segments, and focuses on sustainable pricing, customer service, and product innovation to remain successful.
Tenet Healthcare Corporation reported net income of $70 million for the first quarter of 2006, compared to a net loss of $4 million in the first quarter of 2005. Revenues increased 0.2% to $2.357 billion for same-hospital operations due to a 3.1% increase in compact-adjusted net operating revenues, which excludes discounts provided to uninsured patients. Same-hospital admissions declined 3.3% to 161,756 due to factors such as competition and challenges retaining physicians.
Gruppo Banca IFIS - 2017 preliminary results presentationBanca Ifis
This document provides a summary of key financial information for a company for the fiscal year 2017. Preliminary results show net profit of €180.8 million, an increase of 5.5% compared to the previous fiscal year when normalized. Total assets grew 8.6% to €6.4 billion. The common equity tier 1 ratio remained strong at 15.64%. Business segments like trade receivables and corporate banking saw loan growth while maintaining stable credit quality.
- Q3 2017 company sales grew 4.7% at CER to €9.1 billion, driven by specialty care and vaccines franchises. Diabetes sales declined 14.8% due to losses of exclusivity.
- Specialty care grew 13.9% led by strong Dupixent sales in the US and Kevzara gaining 15% of the IL-6 market share. Vaccines grew 7.2% with strong pediatric combination vaccine sales.
- Consumer healthcare grew 1% with emerging markets up 6.7% offsetting declines in developed markets due to increased competition.
Similar to Zynex December 2013 Investor Presentation (20)
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
UnityNet World Environment Day Abraham Project 2024 Press Release
Zynex December 2013 Investor Presentation
1.
2. Forward Looking Statements
Statements made in this presentation include financial estimates and forward-looking
statements that are not historical facts. Each of these estimates and forward-looking
statements involves risk and uncertainties. These estimates are based on present
circumstances, information currently available, and assumptions about future
revenues, industry growth, and general economic conditions. Estimates are inherently
uncertain as they are based on assumptions concerning future events. No
representations can be made as to the accuracy of such information or the reliability
of such assumptions. Accordingly, actual revenues and expenditures may vary
significantly from the Company’s estimates, and actual results or developments may
differ materially from those expressed or implied by the forward-looking statements.
Factors that could cause actual results to differ from the financial estimates and
forward-looking statements in this presentation include those described in the
Company’s filings with the Securities and Exchange Commission, including the “Risk
Factors” section of the Company’s Annual Report on Form 10-K for the year ended
December 31, 2012, as updated in 2013 quarter periods. Therefore, neither the
Company’s estimates nor the assumptions upon which they are based are to be
interpreted as a guarantee or promise of the Company or management. The
Company has no obligation to modify, amend, update, alter, or change the estimates
contained herein.
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com
OTCQB: ZYXI
12/19/2013
2
3. Zynex Overview
•
Medical Device Manufacturer & Compound Pharmacy
o Non-invasive, conservative pain treatment
o EEG & Sleep diagnostics
o Blood volume monitoring
o Physician and hospital billing
o International sales
•
•
Publicly Traded OTCQB: ZYXI
In operation since 1996, headquartered in Lone Tree, Colorado
•
•
•
>40%+ recurring revenue with more than 200,000 patients treated since inception
High GPM of >70%
Estimated $6b market
OTCQB: ZYXI
12/19/2013
3
5. Business Unit Summary
•
ZYNEX MEDICAL (ZMI)
o Non-invasive electrotherapy pain management devices “TENS” (98% of historical
revenue)
• RX required, insurance billed
• >70% GP, >40% recurring revenue (consumable supplies)
o Topical/transdermal pain cream (introduced Dec 2013)
• RX required, insurance billed, complimentary to TENS
• Expect >80% GP and recurring monthly refill prescriptions
•
ZYNEX NEURODIAGNOSTICS (ZND)
o EEG and sleep diagnostics B:B products (1% of historical revenue)
•
ZYNEX MONITORING SOLUTIONS (ZMS)
o In development, non-invasive blood volume monitor (Zero revenue, in
development)
•
ZYNEX BILLING AND CONSULTING (ZBC)
o Outsourced billing for physicians and hospitals (1% of historical revenue)
•
ZYNEX INTERNATIONAL (ZINT)
o International conduit for all Zynex products (1% of historical revenue-all divisions)
OTCQB: ZYXI
12/19/2013
5
6. Products – Zynex Medical
•
Complete line of electrotherapy pain
management devices-FDA cleared and CE
marked
•
Augments healing, alleviates swelling through
increased blood circulation, and reduces both
acute/chronic pain through the use of
electrical currents
NexWave
•
Consumables required
TruWave+
•
Require a prescription
E-Wave
•
Reimbursed by health insurance
•
May be rented or purchased
IF8000
IF8100
Iontophoresis
Consumables (battery/electrode)
OTCQB: ZYXI
12/19/2013
6
7. Products – Zynex Medical
•
Stroke/spinal cord rehabilitation
devices-FDA cleared and CE
marked
•
Augment healing, as well as
assist in recovery for stroke,
Spinal Cord Injuries and
Traumatic Brain Injury, retrains
muscles, increases range of
motion
NeuroMove
Consumables (electrodes)
•
Consumables required
OTCQB: ZYXI
12/19/2013
7
8. Products – Zynex Neurodiagnostics
•
EEG/Sleep diagnostic devices used
in Neuro clinics, sleep diagnosis labs
and for home sleep diagnosis
•
B:B sale
•
BWIII – (in lab)
Not dependent on insurance
reimbursement
Sleep Diagnostic product
Sleep Profiler– (home)
Sleep Diagnostic product
OTCQB: ZYXI
12/19/2013
8
9. Products – Monitoring Solutions
•
In development – non invasive blood
volume monitor
•
Used in operating and recovery
rooms to detect blood loss and
internal bleeding
•
Clinical trials commenced
•
Patent filed
Blood Volume Monitor
(in development)
OTCQB: ZYXI
12/19/2013
9
13. Available Market
PAST AVAILABLE MARKET ~$4B
ZYNEX MEDICAL
Electrotherapy Devices
CURRENT AVAILABLE MARKET ~$7B
ZYNEX MEDICAL
$550M
Electrotherapy Devices
Compound Pain Cream
ZYNEX MONITORING SOLUTIONS
Cardiac Monitoring Devices
ZYNEX MONITORING SOLUTIONS
$3B
ZYNEX NEURODIAGNOSTICS
Biofeedback/Rehab
$275M
$1.8B
Cardiac Monitoring Devices
$3B
ZYNEX NEURODIAGNOSTICS
$220M
Biofeedback/Rehab
$220M
Sleep Diagnostics
EEG/Epilepsy Monitoring
Sleep Therapy
High Definition EEG
Intraoperative EEG Monitoring
Brain Mapping/Research
$360M
$270M
$120M
$425M
$275M
$100M
Market size based on internal management estimates and various market sources
OTCQB: ZYXI
12/19/2013
13
14. What Happened to Business
•
Electrotherapy Industry (Zynex Medical – TENS)
o Healthcare Reform
• CMS Decision TENS devices
o Lower Back Pain indication no longer covered by Medicare
• Affordable Care Act
o Commercial insurance following CMS
o Physicians confused by general “reform” change and required to generate
significantly more paperwork
o Harder to obtain prescriptions
OTCQB: ZYXI
12/19/2013
14
15. •
Zynex Path to Recovery
Zynex
• Improve current TENS business as quickly as possible
• Expense reductions to current demand (headcount/other ancillary)
• Renegotiated current building lease
• Focus on workers compensation electrotherapy (TENS) orders (highest
collection rate)
• Diversification
• Pain Cream
o Created in-house compound pharmacy (topical pain creams)
o Utilize existing TENS sales channel (same order point as core
business (TENS)) and existing infrastructure
o High insurance reimbursement
o Large market (~1.8b)
o Complements non-invasive pain management TENS device,
places Zynex as a “full service” conservative pain management
company
o High gross profit >80%
• Zynex NeuroDiagnostic
o Growing EEG/sleep market
o Not dependent on insurance reimbursement
o B:B
o Product development
OTCQB: ZYXI
12/19/2013
15
16. Zynex Path to Recovery
• Zynex Monitoring Solutions
oUntapped market need blood volume monitoring (safer surgery/recovery)
oNon-invasive
oB:B
oProduct development
• Zynex Billing and Consulting
oService based revenue
oLeverage insurance billing core competency
OTCQB: ZYXI
12/19/2013
16
17. Zynex – Looking Forward
•
Zynex Medical (ZMI)
o Pain Cream/Compound Pharmacy facts
• Complements Zynex TENS non-invasive pain management product and
is sold through same TENS channel and customer
• Highly fragmented with low concentration
• Approximately 80%+ GM
•
Zynex NeuroDiagnostics(ZND)
o EEG/Sleep Diagnostic distributor agreements
• Adds product breadth to ZND
• Market/End Users
o EEG Diagnostic – Neurology hospital and private practice doctors
o Sleep Diagnostic – Hospital, private practice sleep labs, home use
(portable)
o Sleep Treatment – End user home treatment (Apnea)
OTCQB: ZYXI
12/19/2013
17
18. Zynex – Looking Forward
•
Zynex Monitoring Solutions:
o Blood Volume Monitor at commercialization
• Early warning that patient condition is likely to deteriorate
• Utilizes multiple physiological
• Enables a higher level of care than traditional vital sign monitoring
• Effective in multiple care environments (e.g. operating room, recovery and
trauma)
•
Zynex Billing and Consulting(ZBC)
o Insurance billing and consulting for physicians and hospitals
o Looking to assume/acquire additional billing companies
o Provides recurring service based revenue, while leveraging insurance billing core
competency
OTCQB: ZYXI
12/19/2013
18
19. Future Objectives
•
•
•
•
•
•
•
Listing on AMEX/NASDAQ
Develop devices and applications with high GPM
Continue to grow recurring revenue
Take only calculated risks
Continue net earnings growth plan
Positive free cash flow
Utilize a mix of acquisitions and organic based growth to drive valuation=stock
price=private equity with low dilution and/or loan-based financing
OTCQB: ZYXI
12/19/2013
19
22. Management Team Bio
Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive
Officer of Zynex, Inc. since founding the company in 1996. He has previously held
management positions with companies such as ITT, Siemens, GN Danavox, Dataco
and Philips. Most of his work has been in the areas of international sales and
distribution, technology transfers, mergers and marketing management in the
semiconductor, telecommunications, data communications and medical equipment
industries. Mr. Sandgaard has a degree in electronics engineering from Denmark’s
Odense University of Engineering and an MBA from Copenhagen Business School.
Mr. Sandgaard has an in-depth knowledge of the industry and is the driving force as
to the Company strategies.
Anthony Scalese has been Chief Financial Officer of Zynex, Inc. since September 2010.
Mr. Scalese has over 15 years of experience in accounting, finance and operations
and has spent the past 13 years of his career in the high-tech and healthcare
industries. His most recent position was Chief Financial Officer for Qualmark
Corporation, in which he also served as President for various subsidiaries of
Qualmark. He previously held positions at Coram Healthcare (now Apria Healthcare)
as well as Foundation Health Systems (now Healthnet). Mr. Scalese is a Certified
Public Accountant licensed in Colorado, received a Masters in Business
Administration from the University of Colorado and a Bachelor of Science in Business
Administration-Accounting from Colorado State University.
OTCQB: ZYXI
12/19/2013
22
23. Management Team Bio
Robert "Bob" Cozart is the VP of Technical Operations who develops and manages all
of the teams that make up the Purchasing, Production, Service, Warehouse,
Facilities, and Shipping and Receiving departments. Mr. Cozart has over 26 years of
management experience in electronics manufacturing, primarily with Class II and
Class III medical devices with such companies as HEI, Colorado Medtech,
Pfizer/Valleylab and Medtronic. Mr. Cozart holds an MBA from Creighton University in
Omaha and a BS in Business from the University of Colorado in Boulder.
Robert Bird is the Vice President of Sales responsible for all domestic sales
within the rehabilitation and pain management markets and directs all
domestic sales activities for the Zynex Medical division of Zynex. Mr. Bird
has over 20 years of sales and management experience and holds a B.S.
Degree in Business Administration from California State University,
Hayward.
Dave Empey is the Director of Regulatory and Compliance for Zynex Inc. Mr.
Empey has over 35 years of healthcare, clinical services, management,
operations, medical equipment, accreditation, quality and compliance
experience. Mr. Empey holds an MBA from the University of Denver and is a
Registered Respiratory Therapist.
OTCQB: ZYXI
12/19/2013
23
24. Summary
•
High GPM of >70%
•
•
•
>40%+ recurring revenue
•
>200,000 patients helped since
inception
•
Estimated $7b market
>40,000 units in the field
OTCQB: ZYXI
12/19/2013
24
25. Contact Information
For more information, please contact:
Investor Relations
Zynex, Inc.
9990 Park Meadows Drive
Lone Tree, CO 80124
Telephone: (303) 703-4906 Facsimile: (303) 347-9153
www.zynex.com
OTCQB: ZYXI
12/19/2013
25